Role of piperine in CNS diseases: pharmacodynamics, pharmacokinetics and drug interactions

被引:17
|
作者
Ren, Tianjing [1 ]
Zuo, Zhong [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China
关键词
Piperine; CNS effects; pharmacokinetics; pharmacodynamics; interaction; ENHANCED ORAL BIOAVAILABILITY; BLACK PEPPER; IN-VITRO; TISSUE DISTRIBUTION; LONGUM L; INDUCED NEURODEGENERATION; INDUCED NEUROTOXICITY; URINARY METABOLITE; PUNGENT COMPONENT; MONOAMINE-OXIDASE;
D O I
10.1080/17425255.2019.1672658
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Piperine, the major bioactive component from black pepper, has gained increasing attention for its beneficial effects in the central nervous system (CNS). However, its related pharmacodynamics and brain pharmacokinetics, as well as its interaction with other CNS drugs are lacking, which may hinder its therapeutic and safe use. Areas covered: The current review provides an updated summary on CNS activities of piperine, including anti-epileptic, anti-depressive and neurodegeneration protection effect. The brain pharmacokinetic properties of piperine together with the approaches to enhance its aqueous solubility were summarized. Considering the wide use of black pepper and the well-reported alteration on CYP and transporters by piperine, interactions between piperine and CNS drugs are also illustrated for the first time. Expert opinion: Although the CNS beneficial effects of piperine have been extensively studied in preclinical models, clinical evidence on its CNS application is barely available, which may be attributed to its limited aqueous solubility, unclear pharmacokinetic properties in humans and potential toxicities during long-term use at higher doses. Although beneficial interactions between piperine and certain CNS drugs were often reported in preclinical studies, more mechanistic studies with clinically relevant doses should be conducted to provide guidance on their clinical combination use.
引用
收藏
页码:849 / 867
页数:19
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors
    Jackson, A
    Taylor, S
    Boffito, M
    AIDS REVIEWS, 2004, 6 (04) : 208 - 217
  • [22] Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges
    Zhao, Di
    Huang, Ping
    Yu, Li
    He, Yu
    CLINICAL PHARMACOKINETICS, 2024, 63 (07) : 919 - 944
  • [23] Pharmacokinetics (PK) and CNS pharmacodynamics (PD) of diphenhydramine (DIP)
    Slattum, PW
    Briggs, GC
    Hawley, JM
    Garnett, WR
    Venitz, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI78 - PI78
  • [24] Integrated pharmacokinetics and pharmacodynamics in drug development
    Dingemanse, Jasper
    Appel-Dingemanse, Silke
    CLINICAL PHARMACOKINETICS, 2007, 46 (09) : 713 - 737
  • [25] Journey of a drug: teaching pharmacokinetics and pharmacodynamics
    Neu, Tricia
    Johnson, Ashlyn M.
    TEACHING AND LEARNING IN NURSING, 2024, 19 (03) : e580 - e583
  • [26] Integrated Pharmacokinetics and Pharmacodynamics in Drug Development
    Jasper Dingemanse
    Silke Appel-Dingemanse
    Clinical Pharmacokinetics, 2007, 46 : 713 - 737
  • [27] Neurobiology, pharmacokinetics and pharmacodynamics of drug abuse
    Kim, So Yeon
    Lee, Jong Seok
    Han, Dong Woo
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2013, 56 (09): : 762 - 770
  • [28] Predicting drug–drug interactions through drug structural similarities and interaction networks incorporating pharmacokinetics and pharmacodynamics knowledge
    Takako Takeda
    Ming Hao
    Tiejun Cheng
    Stephen H. Bryant
    Yanli Wang
    Journal of Cheminformatics, 9
  • [29] Piperine and Its Role in Chronic Diseases
    Derosa, Giuseppe
    Maffioli, Pamela
    Sahebkar, Amirhossein
    ANTI-INFLAMMATORY NUTRACEUTICALS AND CHRONIC DISEASES, 2016, 928 : 173 - 184
  • [30] Pharmacokinetics and pharmacodynamics of drug-drug interactions in hospitalized older adults treated with direct oral anticoagulants
    Decaix, Theodore
    Kemache, Kenza
    Gay, Pierre
    Ketz, Flora
    Laprevote, Olivier
    Pautas, Eric
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 (01)